Abstract:Heba Abdel-Halim, 1, *, † Malak Hajar 1, † , Luma Hasouneh 1, † , Suzanne MA Abdelmalek 2, † 1 Department of Medicinal Chemistry, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan; 2 Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan †Dr Abdel-Halim passed away on July 14, 2022 *These authors contributed equally to this work Correspondence: Suzanne MA Abdelmalek, Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, 11196, Jordan, Tel +962-6-5799555 Ext. (8310), Fax +962-65715570, Email Purpose: The development of effective treatments for coronavirus infectious disease 19 (COVID-19) caused by SARS-Coronavirus-2 was hindered by the little data available about this virus at the start of the pandemic. Drug repurposing provides a good strategy to explore approved drugs' possible SARS-CoV-2 antiviral activity. Moreover, drug synergism is essential in antiviral treatment due to improved efficacy and reduced toxicity. In this work, we studied the effect of approved and investigational drugs on one of SARS-CoV-2 essential proteins, the main protease (M pro ), in search of antiviral treatments and/or drug combinations. Methods: Different possible druggable sites of M pro were identified and screened against an in-house library of more than 4000 chemical compounds. Molecular dynamics simulations were carried out to explore conformational changes induced by different ligands' binding. Subsequently, the inhibitory effect of the identified compounds and the suggested drug combinations on the M pro were established using a 3CL protease (SARS-CoV-2) assay kit. Results: Three potential inhibitors in three different binding sites were identified; favipiravir, cefixime, and carvedilol. Molecular dynamics simulations predicted the synergistic effect of two drug combinations: favipiravir/cefixime, and favipiravir/carvedilol. The in vitro inhibitory effect of the predicted drug combinations was established on this enzyme. Conclusion: In this work, we could study one of the promising SARS-CoV-2 viral protein targets in searching for treatments for COVID-19. The inhibitory effect of several drugs on M pro was established in silico and in vitro assays. Molecular dynamics simulations showed promising results in predicting the synergistic effect of drug combinations. Keywords: molecular dynamics simulations, ligand docking, multiple binding sites, drug synergy, SARS-CoV-2 The outbreak of COVID-19 was declared a pandemic by the World Health Organization in March 2020. Almost 520 million cases and more than 6 million deaths were reported. Many drugs that have been used since the outbreak's start were proven futile in compacting the infection. Recently, a newly developed drug was approved for clinical use in severe or critical COVID-19 conditions. However, more drugs are still needed to reduce the impact of this pandemic. Due to the limited time and the urgent need for a treatment, we proposed an in silico approach to explore the effect of approved drugs on one of the important virus targets, the main protease (M pro ). In this work, we have established the inhibitory effect of three drugs and two drug combinations on this enzyme. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1 With more than 520 million people infected and around 6 million reported deaths, COVID-19 represents a serious menace to the world's public health and economies. 2 Many of the treatment approaches that have been employed since the beginning of the pandemic were proven ineffective in targeting the virus. 3–5 Therefore, there is an imminent need to identify drugs that can be effectively used to treat COVID-19. Coronaviruses are enveloped single-stranded positive-sense RNA viruses that belong to the family Coronaviridae . They are widely distributed in humans and other mammals. 6 The SARS-CoV has a large genome (comprised of ≈29,700 nucleotides) that encodes structural and non-structural proteins. 7 The virus replication and transcription occurs at cytoplasmic membranes and involves RNA synthesis mediated by the viral replicase gene products. The replicase gene of SARS-CoV-2 encodes two overlapping polyproteins–pp1a and pp1ab–that are required for viral replication and transcription. 8 Extensive proteolytic processing of these polypeptides takes place by the activity of the 33.8-kDa M<s -Abstract Truncated-

Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.

Combined Drug Repurposing and Virtual Screening Strategies with Molecular Dynamics Simulation Identified Potent Inhibitors for SARS-CoV-2 Main Protease (3Clpro)

An in-silico evaluation of COVID-19 main protease with clinically approved drugs

Discovering Potent Inhibitors Against the Mpro of the SARS-CoV-2. A Medicinal Chemistry Approach

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA

Potential Inhibitors from Natural Compounds against SARS‐CoV‐2 Main Protease: A Systematic Molecular Modelling Approach

Exploring the efficacy of natural compounds against SARS-CoV-2: A synergistic approach integrating molecular docking and dynamic simulation

Unveiling the multitargeted potential of N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine (NSL-CG) against SARS CoV-2: a virtual screening and molecular dynamics simulation study

Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings

Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study

Computational Assessment of Clinical Drugs against SARS‐CoV‐2: Foreseeing Molecular Mechanisms and Potent Mpro Inhibitors

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of covid-19

Drug Repurposing to find Inhibitors of SARS-CoV-2 Main Protease

Repurposing Low-Molecular-Weight Drugs Against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2